Thank you for visiting RefleXion. If you are in person, please visit our booth (#1703) at the exhibit hall!
SCINTIX® biology-guided radiotherapy from RefleXion is a breakthrough treatment that detects and responds to signals emitted from the cancer itself and, for the first time, uses them to autonomously direct precise radiation. This novel treatment elevates the performance of injected radiopharmaceuticals to transform tumors into real-time biological beacons through the novel use of PET. The RefleXion® X1 machine and the tumor communicate continuously via a live data stream produced during patient treatment to enable radiotherapy for all stages of cancer.
Cleared for use in FDG-guided treatment of lung or bone tumors that arise from primary or metastatic disease, SCINTIX therapy expands the use of radiotherapy to patients with advanced-stage disease. SCINTIX therapy solves the conundrum of targeting and managing motion by using real-time emissions from the tumor - as opposed to images taken minutes or even days before. Effective January 1, 2024, CMS established accretive reimbursement for patients treated with SCINTIX therapy.
If you are attending the 2024 SNMMI Annual Meeting in person, please visit RefleXion at Booth 1703.
For more information, please visit reflexion.com or contact us at marketinginfo@reflexion.com. Stay updated with RefleXion by following our LinkedIn, Facebook, Instagram, X, and YouTube.
Brands: RefleXion X1; SCINTIX biology-guided radiotherapy